Eliminating Legionella by inhibiting BCL-XL to induce macrophage apoptosis

Nature Microbiology

Volumn 1, Issue 3, 2016, Pages

  Speir, Mary ^a   Lawlor, Kate E ^b,c   Glaser, Stefan P ^b,c   Abraham, Gilu ^a   Chow, Seong ^a   Vogrin, Adam ^a   Schulze, Keith E ^a   Schuelein, Ralf ^c   OReilly, Lorraine A ^b,c   Mason, Kylie ^c   Hartland, Elizabeth L ^c   Lithgow, Trevor ^a   Strasser, Andreas ^b,c   Lessene, Guillaume ^b,c   Huang, David C S ^b,c   Vince, James E ^b,c   Naderer, Thomas ^a  

^a MONASH UNIVERSITY   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; NAVITOCLAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; VENETOCLAX; BCL2L1 PROTEIN, MOUSE; PROTEIN BCL X;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL STRAIN; BONE MARROW CELL; CANCER CELL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE DELETION; HOST CELL; INTRACELLULAR KILLING; LEGIONELLA; LEGIONNAIRE DISEASE; LUNG INFECTION; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; GENETICS; GROWTH, DEVELOPMENT AND AGING; LUNG ALVEOLUS MACROPHAGE; MICROBIOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; DISEASE MODELS, ANIMAL; GENE DELETION; LEGIONELLA; LEGIONELLOSIS; MACROPHAGES, ALVEOLAR; MICE;

EID: 85010270989     PISSN: None     EISSN: 20585276     Source Type: Journal    
DOI: 10.1038/nmicrobiol.2015.34     Document Type: Article

References (36)

1. Cunha, B. A., Burillo, A., & Bouza, E. Legionnaires? disease. Lancet http://dx.doi.org/10.1016/S0140-6736(15)60078-2 (2015).
2. Newton, H. J., Ang, D. K., van Driel, I. R., & Hartland, E. L. Molecular pathogenesis of infections caused by Legionella pneumophila. Clin. Microbiol. Rev. 23, 274-298 (2010).
3. O?Connor, T. J., Boyd, D., Dorer, M. S., & Isberg, R. R. Aggravating genetic interactions allow a solution to redundancy in a bacterial pathogen. Science 338, 1440-1444 (2012).
4. Lock, K., et al. Public health and economic costs of investigating a suspected outbreak of Legionnaires? disease. Epidemiol. Infect. 136, 1306-1314 (2008).
5. Losick, V. P., & Isberg, R. R. NF-κB translocation prevents host cell death after low-dose challenge by Legionella pneumophila. J. Exp. Med. 203, 2177-2189 (2006).
6. Abu-Zant, A., et al. Anti-Apoptotic signalling by the Dot/Icm secretion system of L. pneumophila. Cell Microbiol. 9, 246-264 (2007).
7. Strasser, A., Cory, S., & Adams, J. M. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 30, 3667-3683 (2011).
8. Lessene, G., Czabotar, P. E., & Colman, P. M. BCL-2 family antagonists for cancer therapy. Nature Rev. Drug Discov. 7, 989-1000 (2008).
9. Ren, T., Zamboni, D. S., Roy, C. R., Dietrich, W. F., & Vance, R. E. Flagellindeficient Legionella mutants evade caspase-1-And Naip5-mediated macrophage immunity. PLoS Pathog. 2, e18 (2006).
10. Molofsky, A. B., et al. Cytosolic recognition of flagellin by mouse macrophages restricts Legionella pneumophila infection. J. Exp. Med. 203, 1093-1104 (2006).
11. Van Delft, M. F., et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389-399 (2006).
12. Souers, A. J., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Med. 19, 202-208 (2013).
13. Tao, Z. F., et al. Discovery of a potent and selective BCL-XL inhibitor with in vivo activity. ACS Med. Chem. Lett. 5, 1088-1093 (2014).
14. Wei, M. C., et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727-730 (2001).
15. Nogueira, C. V., et al. Rapid pathogen-induced apoptosis: a mechanism used by dendritic cells to limit intracellular replication of Legionella pneumophila. PLoS Pathog. 5, e1000478 (2009).
16. Chen, L., et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17, 393-403 (2005).
17. Bae, J., Leo, C. P., Hsu, S. Y., & Hsueh, A. J. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J. Biol. Chem. 275, 25255-25261 (2000).
18. Adams, K. W., & Cooper, G. M. Rapid turnover of MCL-1 couples translation to cell survival and apoptosis. J. Biol. Chem. 282, 6192-6200 (2007).
19. Okamoto, T., et al. Enhanced stability of MCL1, a prosurvival BCL2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis. Proc. Natl Acad. Sci. USA 111, 261-266 (2014).
20. Fontana, M. F., et al. Secreted bacterial effectors that inhibit host protein synthesis are critical for induction of the innate immune response to virulent Legionella pneumophila. PLoS Pathog. 7, e1001289 (2011).
21. Ivanov, S. S., & Roy, C. R. Pathogen signatures activate a ubiquitination pathway that modulates the function of the metabolic checkpoint kinase mTOR. Nature Immunol. 14, 1219-1228 (2013).
22. Cambronne, E. D., & Roy, C. R. The Legionella pneumophila IcmSW complex interacts with multiple Dot/Icm effectors to facilitate type IV translocation. PLoS Pathog. 3, e188 (2007).
23. Shen, X., et al. Targeting eEF1A by a Legionella pneumophila effector leads to inhibition of protein synthesis and induction of host stress response. Cell Microbiol. 11, 911-926 (2009).
24. Belyi, Y., et al. Legionella pneumophila glucosyltransferase inhibits host elongation factor 1A. Proc. Natl Acad. Sci. USA 103, 16953-16958 (2006).
25. Mohr, I., & Sonenberg, N. Host translation at the nexus of infection and immunity. Cell Host Microbe 12, 470-483 (2012).
26. McEwan, D. L., Kirienko, N. V., & Ausubel, F. M. Host translational inhibition by Pseudomonas aeruginosa exotoxin A triggers an immune response in Caenorhabditis elegans. Cell Host Microbe 11, 364-374 (2012).
27. Gobin, I., Susa, M., Begic, G., Hartland, E. L., & Doric, M. Experimental Legionella longbeachae infection in intratracheally inoculated mice. J. Med. Microbiol. 58, 723-730 (2009).
28. Gomez-Valero, L., Rusniok, C., Cazalet, C., & Buchrieser, C. Comparative and functional genomics of Legionella identified eukaryotic like proteins as key players in host-pathogen interactions. Front. Microbiol. 2, 208 (2011).
29. Tse, C., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421-3428 (2008).
30. Ebert, G., et al. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proc. Natl Acad. Sci. USA 112, 5803-5808 (2015).
31. Edelstein, P. H. Control of Legionella in hospitals. J. Hosp. Infect. 8, 109-115 (1986).
32. Harding, C. R., et al. The Dot/Icm effector SdhA is necessary for virulence of Legionella pneumophila in Galleria mellonella and A/J mice. Infect. Immun. 81, 2598-2605 (2013).
33. Cazalet, C., et al. Analysis of the Legionella longbeachae genome and transcriptome uncovers unique strategies to cause Legionnaires? disease. PLoS Genet. 6, e1000851 (2010).
34. Bauernfeind, F. G., et al. Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183, 787-791 (2009).
35. Croker, B. A., et al. Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1. Proc. Natl Acad. Sci. USA 108, 13135-13140 (2011).
36. Leverson, J. D., et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci. Transl. Med. 7, 279ra40 (2015).